FLGR-242 for Muscle Growth

Evidence Review created on 09/13/2026 using AI4L / Opus 5

Also known as: FLGR242, Recombinant Follistatin FLGR242, Follistatin FLGR242

Motivation

FLGR-242 is an engineered protein sold online as a research compound. It copies part of follistatin, a protein the body makes to neutralize myostatin — the signal muscle tissue uses to put a ceiling on its own growth. Lifting that ceiling is one of the few known ways to add muscle without training harder or eating more, which is why the target draws attention from drug developers and from people trying to hold muscle as they age.

The idea is not new. Cattle bred without a working myostatin signal carry startling amounts of muscle, and large companies have spent two decades building drugs and gene therapies that try to reproduce that state. FLGR-242 belongs to a different lineage: it appeared on peptide vendor websites rather than in a clinical program, is marketed as a longer-lasting and more selective follistatin, and is sold labeled for laboratory use only.

This review examines what is known about FLGR-242 itself, what must be inferred from compounds acting on the same signal, where those studies agree and conflict, how it is used outside formal medicine, and what can be measured to track change.

Benefits - Risks - Protocol - Conclusion

Grokipedia

No Grokipedia article exists for FLGR-242.

Examine

No Examine article exists for FLGR-242. Examine covers dietary supplements and nutrients sold for human consumption, and FLGR-242 is neither — it is an unapproved injectable protein distributed for laboratory use.

ConsumerLab

No ConsumerLab article exists for FLGR-242. ConsumerLab tests retail supplements for identity and purity and does not review injectable research compounds.

Systematic Reviews

No systematic reviews or meta-analyses for FLGR-242 were found on PubMed as of September 13, 2026.

Neither side of the trade-off is represented in the systematic-review literature: there is no systematic review or meta-analysis of FLGR-242 for muscle growth, and none covering its principal risk, the off-target blockade of related growth factors. Reviews of other agents acting on this pathway exist and are cited elsewhere in this document, but none of them is a review of FLGR-242.

Mechanism of Action

Skeletal muscle size is held down by myostatin (also called GDF-8, growth differentiation factor 8), a circulating protein of the transforming growth factor beta (TGF-β) superfamily — a family of signals that govern tissue growth. Myostatin docks on the activin type IIB receptor (ActRIIB) on the muscle-fiber surface, which activates Smad2/3 (messengers that carry the signal into the nucleus), switching on genes that restrain protein building and damping the mTOR (mechanistic target of rapamycin, the cell’s master switch for protein synthesis) growth pathway. Follistatin acts one step earlier, trapping myostatin, activin A, activin B and GDF-11 (growth differentiation factor 11, a close relative of myostatin) outside the cell before they reach the receptor.

FLGR-242 is described by its vendor as a follistatin fragment built on the FS I-I domain pair (the first two of follistatin’s binding modules) and fused through a glycine–serine linker to an albumin-binding sequence. Three properties are claimed, none published: weak heparin binding, so the molecule spreads through the circulation instead of lodging where it is injected; weaker activin binding than natural follistatin; and tight binding to blood albumin, stretching a natural half-life of one to two hours toward weeks. Being a protein, it bypasses the cytochrome P450 enzymes (CYP, the liver’s main drug-metabolizing family); clearance would be by breakdown to amino acids and uptake by kidney and scavenger cells. A competing reading holds that follistatin’s muscle effect depends heavily on blocking activin A; sparing activin would then forfeit much of the effect being sold.

Historical Context & Evolution

Myostatin was identified in 1997 as the growth factor whose loss produces double-muscled cattle, and the same kind of mutation was later found in a child with unusual muscle bulk. The original purpose of every agent in this class was therapeutic: to rebuild muscle in muscular dystrophy, spinal muscular atrophy (an inherited motor-nerve disease causing progressive weakness) and inclusion body myositis (a late-onset inflammatory muscle disease).

Every trial named below was designed, funded and reported by the company that owned the molecule. The first antibody, stamulumab, was tolerated in adult muscular dystrophy but produced no strength gain. Decoy receptors followed; ACE-031 raised lean mass in healthy postmenopausal women, then its dystrophy program was halted after nosebleeds and small dilated skin vessels appeared. Gene delivery of follistatin enlarged and strengthened monkey quadriceps, which pushed follistatin from a laboratory reagent toward a therapy. Acceleron then built ACE-083, a follistatin-based trap designed to stay where injected; it enlarged muscle in facioscapulohumeral muscular dystrophy (a dystrophy affecting face, shoulder and upper-arm muscles) without consistent functional benefit, and was discontinued.

These outcomes were not refutations of the biology. Muscle grew every time; what failed was the translation into strength, and in one case the breadth of the blockade. Health-optimization interest followed the mass findings rather than the functional ones, and by 2025 follistatin fragments were being sold directly to consumers. FLGR-242 entered that market as an engineered answer to the two limits the clinical programs exposed — short duration and off-target blockade.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: High requires a human clinical endpoint or a validated clinical surrogate replicated across more than one trial of the intervention, and FLGR-242 has never been given to a human being in any recorded study.

Medium 🟩 🟩

No benefit reaches Medium: Medium requires that same class of human outcome in a single trial or in consistent observational data on the intervention, and no trial or cohort of any size has measured FLGR-242.

Low 🟩

Increase in Skeletal Muscle Mass

Blocking this pathway adds muscle tissue in people, but only other molecules have been tested. One dose of the decoy receptor ACE-031 raised lean mass in healthy postmenopausal women; the follistatin-based trap ACE-083 enlarged injected muscles in facioscapulohumeral muscular dystrophy. FLGR-242 itself is untested.

Magnitude: +3.3% total lean mass and +5.1% thigh muscle volume 29 days after a single 3 mg/kg dose of ACE-031; +16.4% biceps and +9.5% tibialis anterior volume with ACE-083 over six months.

Improved Physical Function ⚠️ Conflicted

Whether added mass becomes usable capacity is genuinely disputed. A meta-analysis of bimagrumab walking data found a small gain; a meta-analysis in sarcopenia (age-related muscle loss) found none in strength or gait speed, and the ACE-083 dystrophy trial found none. Net reading: size increases, function usually does not.

Magnitude: +10 m on the six-minute walk test pooled across four bimagrumab trials, with a standard error of 5 (the typical margin of error around that estimate) and p = 0.05 (a result this large would arise by chance about one time in twenty); no significant change in grip or knee-extensor strength in the sarcopenia pooling.

Reduction in Fat Mass ⭕️ Not Central to Muscle Growth

Blocking this receptor strips fat as reliably as it adds muscle, an effect on body composition rather than on muscle growth. Pooled randomized trials in obesity and type 2 diabetes show substantial fat loss alongside lean gain with bimagrumab, an antibody, not with any follistatin-derived agent.

Magnitude: −4.72 kg fat mass and −4.85 kg body weight versus placebo across four randomized trials of bimagrumab; −20.5% total fat mass over 48 weeks in the type 2 diabetes trial.

Improved Insulin Sensitivity ⭕️ Not Central to Muscle Growth

Muscle is the main site of glucose disposal, so enlarging it may improve blood sugar handling — a metabolic outcome, not muscle growth. Evidence comes from a randomized bimagrumab trial in type 2 diabetes and rodent work, never from FLGR-242.

Magnitude: Glycated hemoglobin fell 0.76 percentage points versus 0.04 on placebo over 48 weeks in that trial; −0.13% pooled across four randomized trials.

Speculative 🟨

Whole-Body Rather Than Local Muscle Growth

FLGR-242’s reduced heparin binding is claimed to give body-wide exposure. The comparator ACE-083 binds heparin tightly and acts only where injected. No measurement of FLGR-242 distribution exists; the basis is design rationale only.

Narrower Off-Target Blockade

The FS I-I design is claimed to spare activin while trapping myostatin. Follistatin forms differ markedly in what they bind, so the premise is sound, but no binding data for FLGR-242 exist. Mechanistic inference only.

Preservation of Muscle During Weight Loss

Rapid weight loss strips lean tissue, and this pathway is being tested as a counterweight. Both relevant trials are ongoing with no results reported. The basis for FLGR-242 is mechanistic extrapolation, not data.

Faster Recovery From Resistance Training

Vendors claim improved recovery between sessions. No controlled study of any myostatin-blocking agent has measured recovery, soreness or repeat-bout performance. The claim rests on marketing copy and anecdote, not on outcome data.

Benefit-Modifying Factors

Myostatin gene variant (MSTN K153R): Carriers of the R variant are over-represented among strength athletes, suggesting altered myostatin processing. Whether carriers respond differently to pharmacological blockade has never been tested.
Baseline circulating myostatin and follistatin: Resistance training already lowers myostatin and raises follistatin. Someone training hard has partly moved these markers already, leaving less headroom than an untrained or immobilized person for a drug to recover.
Baseline lean mass: Trials of this class recruited people with low or declining muscle, and functional gains appeared only in those with the slowest baseline walking. A well-trained adult near their genetic ceiling sits on a part of the response curve never studied.
Sex-based differences: No trial in this class was powered to compare sexes. Women enter with lower absolute lean mass, so an equal absolute gain is a larger relative gain, and the one healthy-volunteer study of a related agent enrolled only postmenopausal women.
Pre-existing conditions: The largest documented gains occurred in muscle disease, sarcopenia and obesity. Chronic inflammation, untreated hypothyroidism or low testosterone independently suppress muscle protein synthesis and would be expected to blunt any response.
Age: Benefits in this class were demonstrated mostly above age 60, where myostatin signaling contributes more to muscle loss. Adults at the older end of the target range plausibly have more to gain in mass, and the least evidence for gains in function.
Concurrent mechanical loading: Removing the brake does not itself supply the growth stimulus. Every trial that gained mass without training also failed to gain strength, making resistance training the factor most likely to decide whether new tissue is usable.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: High requires documented human adverse events or a validated clinical surrogate replicated across more than one trial of the intervention, and no human has been dosed with FLGR-242 under observation.

Medium 🟥 🟥

No risk reaches Medium: Medium requires that same class of human safety outcome from a single trial or consistent observational data on the intervention, and no trial, registry or case series records FLGR-242 exposure.

Low 🟥

Muscle Cramps and Spasms

The most consistent adverse event of this pathway, thought to reflect altered fiber-type composition and calcium handling in rapidly enlarging muscle. It topped the adverse-event list in the inclusion body myositis trial and was dose-related. No follistatin-derived agent has been formally assessed for it, and FLGR-242 not at all.

Magnitude: Risk ratio 10.44 (the event was 10.44 times as likely as on placebo), 95% confidence interval 4.23–25.75 (the range the true value most plausibly occupies), in pooled bimagrumab trials; 51% versus 21% at the highest dose in the inclusion body myositis trial.

Diarrhea

Loose stools track the same receptor blockade, probably through effects on smooth muscle and gut motility. It was the second most frequent adverse event in pooled bimagrumab trials and contributed to withdrawals. Whether a follistatin fragment sparing activin would reproduce it is unknown.

Magnitude: Risk ratio 4.91 (95% confidence interval 2.38–10.11) versus placebo in those pooled trials, where discontinuation carried a risk ratio of 5.75; 52% versus 18% at the highest dose in the inclusion body myositis trial.

Rise in Low-Density Lipoprotein Cholesterol

Pooled randomized trials of bimagrumab show a clear increase in low-density lipoprotein (LDL, the cholesterol-carrying particle that drives artery disease), which runs against the goal of anyone using this class for long-term health. The mechanism is unresolved and no follistatin-derived agent has been examined.

Magnitude: +0.47 mmol/L (approximately +18 mg/dL) versus placebo, 95% confidence interval 0.03 to 0.91, across four randomized trials.

Nosebleeds and Dilated Skin Vessels

Broad blockade at this receptor also blocks bone morphogenetic proteins 9 and 10, which maintain blood-vessel integrity. ACE-031’s dystrophy program was stopped when nosebleeds and telangiectasias (small dilated surface vessels) emerged. A more selective agent should avoid this, but FLGR-242’s selectivity is unverified.

Magnitude: Not quantified in available studies. The trial was halted at the second dosing regimen on emerging safety signals before an event rate could be estimated, and no later study of the class has reported one.

Injection-Site Reactions and Hypersensitivity

Injected protein therapeutics provoke local inflammation and occasionally systemic reactions. Mild-to-moderate injection-site reactions were the commonest adverse event with ACE-083, and stamulumab produced cutaneous hypersensitivity at its two highest doses. Unpurified material raises this risk further.

Magnitude: Reactions rise with repeated intramuscular dosing — they were the most frequent adverse event with ACE-083 and stayed mild or moderate — while hypersensitivity appeared with stamulumab only at its two highest doses, 10 and 30 mg/kg; neither trial report gives a placebo-adjusted incidence figure.

Exposure to Impure or Misrepresented Product

The compound reaches users only through unlicensed suppliers. Systematic analysis of falsified injectable peptides found low purity plus arsenic and lead; gray-market semaglutide vials were grossly overdosed and universally positive for endotoxin (a fever-causing bacterial residue). This is the most likely source of harm.

Magnitude: Purity 5–75% across ten falsified peptide products, with arsenic and lead up to ten times the injectable-product limit set by the International Council for Harmonisation; 7.7–14.37% purity and 2.16–8.95 endotoxin units per mg in purchased semaglutide vials.

Speculative 🟨

Immunogenicity and Neutralizing Antibodies

An engineered non-human protein sequence can raise antibodies that neutralize it or cross-react with native follistatin. No immunogenicity assay has been run on FLGR-242. The concern is structural, not observed.

Reduced Force per Unit of Muscle

Mice lacking myostatin gain bulk but lose specific force, with fewer mitochondria and a shift toward fatigable fibers. Whether pharmacological blockade in adults reproduces this has not been measured in humans.

Disruption of Reproductive Hormone Signaling

Natural follistatin suppresses follicle-stimulating hormone by trapping activin. FLGR-242 is claimed to spare activin, which would avoid this, but no hormone measurements from any user or study exist.

Effects on Bone ⚠️ Conflicted

A decoy receptor raised bone mineral density, while follistatin’s broad blockade is argued to weaken bone by antagonizing bone morphogenetic proteins. Net reading: direction is unresolved and agent-dependent.

Unopposed Growth Signaling in Non-Muscle Tissue

Activin restrains proliferation in several tissues, so sustained blockade is theorized to permit unwanted growth. No tumor signal has appeared in trials of related agents, and none has run long enough to exclude one.

Cardiac Remodeling

Cardiac muscle expresses this receptor, and chronic blockade could alter heart structure. Echocardiography in the inclusion body myositis trial found no adverse cardiac effect, but exposures were short and the molecule was different.

Risk-Modifying Factors

Bone morphogenetic protein pathway variants: Inherited defects in this pathway, as in hereditary hemorrhagic telangiectasia, plausibly compound the vascular fragility seen with broad receptor blockade. Untested, but mechanistically the clearest genetic contraindication in this class.
Myostatin gene variant (MSTN K153R): Variants altering myostatin processing may shift how much ligand a fixed dose must trap, changing the effective exposure. No pharmacogenetic study of any agent in this class has been published.
Baseline LDL cholesterol and apolipoprotein B: Because the class raises LDL, someone starting with already elevated particle counts absorbs that rise from a worse position, which matters more over years than over a trial.
Baseline platelet count and clotting time: Vascular fragility was the signal that stopped one program. Pre-existing thrombocytopenia (a low platelet count) or anticoagulation would amplify any bleeding tendency, and these were exclusion criteria in the relevant trials.
Sex-based differences: No trial in this class reported sex-stratified adverse events. Women have higher baseline circulating follistatin and lower muscle mass, but neither has been shown to change the side-effect profile.
Pre-existing conditions: Active malignancy, chronic kidney or liver disease, and heart failure all shift the balance unfavorably, whether by removing clearance capacity, by adding bleeding risk, or by leaving proliferation less restrained.
Age: Older adults carry more vascular fragility, more medications taken at once and more baseline arterial disease, so the bleeding and LDL signals matter more at the older end of the target range than in a 35-year-old.

Key Interactions & Contraindications

Anticoagulants and antiplatelets (clot-preventing drugs such as warfarin, apixaban, rivaroxaban, clopidogrel): Caution. Additive bleeding risk with the telangiectasia and nosebleed signal of this class. Mitigation: avoidance of the combination, or monthly clotting time and hemoglobin checks where it is unavoidable.
Over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs, pain and swelling reducers such as ibuprofen, naproxen, aspirin): Caution. Platelet inhibition adds to vascular fragility, raising nosebleed and bruising risk. Mitigation: paracetamol substituted for routine pain relief during use.
Glucagon-like peptide-1 receptor agonists (GLP-1, gut-hormone mimics such as semaglutide, tirzepatide): Monitor. Overlapping gastrointestinal effects make diarrhea considerably more likely; the combination is under formal study. Mitigation: initiation staggered by four weeks.
Systemic corticosteroids (steroid anti-inflammatory drugs such as prednisone, dexamethasone): Monitor. Directly opposing effects on muscle protein balance, so steroid courses blunt or reverse any gain. Mitigation: none available beyond recognizing that a steroid course invalidates progress measurement.
Androgens and anabolic steroids (male-hormone drugs such as testosterone, nandrolone, oxandrolone): Caution. Additive anabolic signaling with additive adverse lipid effects, since both raise LDL and lower protective cholesterol. Mitigation: full lipid panel at six weeks rather than twelve.
Statins (cholesterol-lowering drugs such as atorvastatin, rosuvastatin): Monitor. Useful for offsetting the LDL rise, but statin-associated muscle aches are indistinguishable from this class’s cramps. Mitigation: creatine kinase (an enzyme released by damaged muscle) measured before pain is attributed to either agent.
Supplements with additive effects on this pathway (creatine monohydrate, epicatechin, ecdysteroids, urolithin A): Monitor. All are marketed for the same endpoint, making attribution of any change impossible. Mitigation: new supplements held constant across the observation period.
Supplements with additive bleeding effects (high-dose fish oil, ginkgo, garlic extract, vitamin E, nattokinase): Caution. Each impairs platelet function, compounding the vascular fragility signal. Mitigation: combined omega-3 intake kept below 2 g daily, with the rest stopped.
Other interventions (resistance training, caloric restriction, blood-flow-restriction training): Potentiating rather than hazardous. Loading is what converts added tissue into strength; severe caloric restriction removes the substrate. Mitigation: protein intake and progressive loading maintained throughout.

Populations who should avoid FLGR-242:

Anyone with active malignancy or a cancer treated within the past 5 years
Pregnancy, lactation, or active attempts to conceive
Hereditary hemorrhagic telangiectasia, or any bleeding disorder with platelets below 100 × 10⁹/L or international normalized ratio (INR, a measure of how fast blood clots) above 1.5
Chronic kidney disease with estimated glomerular filtration rate (eGFR, kidney filtering capacity) below 30 mL/min/1.73 m²
Liver impairment at Child-Pugh Class B or C (moderate to severe loss of liver function)
Heart failure at New York Heart Association Class III or IV, or myocardial infarction within 90 days
Adults under 25 or anyone whose growth plates have not closed
Competitive athletes in any sport subject to anti-doping testing
Anyone unable to obtain third-party identity, purity and endotoxin certification for the specific batch

Risk Mitigation Strategies

Batch-level third-party testing before first use: An independent identity and purity report plus an endotoxin result below 5 endotoxin units per kg body weight per hour is the check against impure or misrepresented product, the most probable source of harm.
Lipid panel before and at six weeks: Apolipoprotein B and LDL cholesterol at baseline and again at six weeks, with a stop threshold of a 15 mg/dL rise in apolipoprotein B, tracks the documented LDL rise in this class.
Conservative first exposure: A fraction of any circulated dose at first administration, followed by 72 hours of observation, is the common precaution against immediate hypersensitivity and injection-site reactions, which cannot be predicted from an untested sequence.
Full blood count with platelets every eight weeks: Platelets and hemoglobin on a fixed schedule, with any unexplained fall as a stop trigger, covers the bleeding and vascular-fragility signal that terminated the ACE-031 dystrophy program.
Stop rules for bleeding signs: Recurrent nosebleeds, new spider-like skin vessels, or easy bruising serve as immediate discontinuation triggers rather than waiting for a scheduled test. These were the specific events that ended a clinical program in this class.
Separate from other anabolic agents and new supplements: Changing one variable at a time, with training, protein intake and supplements held constant, addresses misattribution, which otherwise conceals both harm and lack of effect.
Progressive resistance training throughout: Loading the muscle being grown at least twice weekly addresses the dominant failure mode of the class, added tissue that never becomes usable strength.
Sterile handling and single-use reconstitution: Reconstitution with bacteriostatic water, refrigeration, and discarding after 28 days address contamination and injection-site infection, a risk aggravated by uncertified starting material.

Therapeutic Protocol

No validated protocol exists: No regulator, clinic or published study has defined a dose for FLGR-242. What circulates comes from vendors and resellers, which is the weakest possible basis for any regimen.
Circulated dose ranges: Vendor and reseller material describes anything from 100–300 mcg daily to 5 mg every other day — a roughly hundredfold spread that reveals guesswork rather than a converging practice.
Comparator dosing from actual trials: The nearest measured regimens are ACE-083 at 240 mg per muscle every three weeks by intramuscular injection, and ACE-031 at 0.02–3 mg/kg subcutaneously.
Competing approaches: Practitioners in this space split between low-dose daily subcutaneous administration and infrequent loading doses, and no expert or clinic has published a rationale distinguishing them. Neither can be called the default.
Route and site: Subcutaneous abdominal injection is what vendors describe. Intramuscular delivery is what the two follistatin-based clinical agents used, because they were designed to act locally.
Best time of day: No chronobiology data exist for this compound or its class. Practitioners who use it generally dose in the morning, on the reasoning that myostatin signaling and cortisol both peak early.
Half-life: Natural follistatin clears within one to two hours; the albumin-binding construct is claimed to extend this to weeks. No measurement in any species has been published, so dosing interval is unanchored.
Single versus split dosing: If the multi-week half-life claim holds, splitting doses is pointless; if it does not, daily microdosing is the only regimen that maintains exposure. The claim is what decides this, and it is unverified.
Genetic factors in dose choice: No pharmacogenetic data exist. Variants in the myostatin gene and in bone morphogenetic protein pathway genes are the plausible candidates for altering either response or vascular risk.
Sex-based differences: No trial in this class was designed to compare sexes, and the one healthy-volunteer study enrolled only women, so no sex-specific dosing guidance can be derived from the literature.
Age-related considerations: Adults in the upper half of the target range have more myostatin-driven muscle loss to reverse and more vascular fragility to risk, which argues for the lower end of any circulated range.
Baseline biomarkers influencing response: Low baseline lean mass, elevated circulating myostatin and a long period of disuse are the conditions under which related agents produced their largest gains.
Pre-existing conditions influencing response: Untreated hypothyroidism, low testosterone, chronic kidney disease and active inflammation each independently suppress muscle protein synthesis and would be expected to limit any response to removing the brake.

Discontinuation & Cycling

Not a lifelong intervention: Nothing in this class has been given continuously beyond about a year in any study, and no long-term exposure data exist. Use is bounded by the absence of safety data rather than by a defined endpoint.
Gains are not permanent: Muscle added by removing an inhibitory signal reverts once the signal returns. No agent in this class has shown gains that persist after withdrawal, and none was designed to.
No withdrawal syndrome described: No rebound, dependence or acute withdrawal effect has been reported for any agent in this class. The expected course after stopping is gradual loss of the added tissue.
No tapering required: Because there is no withdrawal effect and no receptor upregulation documented, abrupt cessation carries no known hazard. Tapering has never been studied in this class.
Cycling is undocumented: Vendors describe 12–16 week cycles, but no study has compared continuous with intermittent dosing, and no loss of effect over time has been demonstrated. The cycle lengths are conventions, not findings.
Immediate stop triggers: Recurrent nosebleeds, new surface vessel lesions, unexplained bruising, or a rise in apolipoprotein B beyond the pre-set threshold are reasons to stop at once rather than complete a cycle.

Sourcing and Quality

No pharmaceutical-grade source exists: FLGR-242 is not made by any licensed manufacturer and is not available from compounding pharmacies. Every supply route is a research-chemical vendor operating outside pharmaceutical quality systems.
Named vendors: BioLongevity Labs markets it as the patent-holding source, with resellers including Peptagon, Stack Science, Alpha BioMed and NutriGenix. Naming them is not endorsement; none operates under pharmaceutical manufacturing oversight.
What to look for: A batch-specific certificate of analysis with mass-spectrometry identity confirmation, purity above 98%, and a bacterial endotoxin result. Analytical labs such as Janoshik and Colmaric are used for independent verification in this market.
Why the certificate matters: Analysis of falsified injectable peptides found purity as low as 5% plus toxic heavy metals, and gray-market semaglutide contradicted its own label in every sample.
Formulation and handling: Supplied as freeze-dried powder, typically 5 or 10 mg per vial. Handling instructions call for reconstitution with bacteriostatic water, refrigeration at 2–8 °C, protection from light, and disposal 28 days after reconstitution.
Identity cannot be confirmed against a standard: No reference material or published sequence for FLGR-242 exists in any public database, so even a competent laboratory cannot confirm that a vial contains what the label claims.

Practical Considerations

Time to effect: Related agents produced measurable lean-mass change within four weeks and plateaued near six months. Any honest assessment of FLGR-242 therefore requires a scan before starting and one at twelve weeks.
Mistaking size for strength: The commonest error is treating a scale or mirror change as proof of benefit. Every trial in this class that measured both found mass rising while strength did not follow.
Trusting the certificate of analysis supplied by the seller: Vendor-issued documents in this market are frequently recycled or fabricated. Independent batch testing is the only meaningful check.
Regulatory status: Not approved anywhere for any indication. The “research use only” label does not exempt a product intended for human use, and warning letters were issued to peptide vendors on that basis in 2025 and 2026.
Prohibited in competitive sport: Myostatin-binding proteins including follistatin are prohibited under the World Anti-Doping Agency list, section S4.3. That agency is funded by governments and the sports movement and earns no revenue from what it lists.
Cost and payer incentives: Roughly 200–400 US dollars per 10 mg vial, entirely out of pocket. No insurer or health system covers it, and its comparator, resistance training, generates no billing either, so no institutional payer has a financial stake in the comparison.
Who produced the evidence: The trials underlying this pathway were funded and run by the companies that owned the molecules, and every description of FLGR-242 itself originates with its seller or with affiliates paid on commission.

Interaction with Foundational Habits

Sleep: No direct interaction is documented. The indirect link runs the other way: growth hormone release and muscle protein synthesis are concentrated in deep sleep, so short sleep caps what any anabolic signal can deliver. Night cramps, the commonest adverse event of this class, may fragment sleep.
Nutrition: Direct and potentiating. Removing a growth brake without supplying substrate achieves nothing, so protein intake around 1.6–2.2 g per kg body weight daily, distributed across three or four meals, is the precondition for any gain. Severe caloric restriction inverts the effect entirely.
Exercise: Potentiating, and the single most important interaction. Blockade of this pathway adds tissue but not strength; mechanical loading is what converts one into the other. Progressive resistance training at least twice weekly, targeting the muscles being measured, is what makes the difference measurable.
Stress management: Indirect and opposing. Chronic cortisol elevation drives muscle protein breakdown through a pathway independent of myostatin, so unmanaged stress works against the intervention without interacting with it pharmacologically. No cortisol data exist for any agent in this class.

Monitoring Protocol & Defining Success

Because no reference data exist for this compound, monitoring is the only way to distinguish effect from expectation. Before any exposure, the baseline panel in common use spans: body composition by scan, a complete lipid panel including particle count, a full blood count with platelets, kidney and liver panels, glycemic markers, and objective strength testing on at least two movements. The purpose of the baseline is comparison, not reassurance — without it, neither benefit nor harm can be attributed. After starting, a short-interval safety check at two weeks catches immediate reactions; lipids and blood count are repeated at six weeks, body composition and strength at twelve weeks, and everything again at six months. Thereafter, if use continues, the same full panel every three to six months is the minimum that would detect the slow-moving signals, particularly the lipid change, that matter most over years.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Lean body mass (DXA scan)	No established target; track ≥1 kg gain from own baseline at 12 weeks	The primary outcome the compound is bought for	DXA is dual-energy X-ray absorptiometry, which separates lean, fat and bone mass. Same machine and hydration state each time; conventional reports give percentages, which obscure absolute change
Apolipoprotein B	<80 mg/dL; <60 mg/dL for those prioritizing arterial risk	Counts artery-damaging particles; this class raises them	Apolipoprotein B is the single protein carried on every artery-damaging particle. Conventional labs often report no range at all or accept <130 mg/dL. Non-fasting is acceptable
LDL cholesterol	<70 mg/dL (1.8 mmol/L)	Directly raised by pooled trials of this class	Conventional reference is <100 mg/dL. Apolipoprotein B is the better paired marker when triglycerides are high
Platelet count	175–350 × 10⁹/L	Falling platelets amplify the bleeding signal of this class	Conventional range extends to 150–450 × 10⁹/L. Reported as part of a full blood count; a repeat measurement precedes attributing any fall to the compound
Hemoglobin	13.5–15.0 g/dL (women), 14.0–16.0 g/dL (men)	Detects hidden blood loss from the nosebleed and telangiectasia signal	Conventional lower limits sit about 1 g/dL below these. A fall of more than 1 g/dL between checks is a stop threshold
Creatine kinase	50–200 U/L	Separates drug-related cramps from genuine muscle damage	Creatine kinase is an enzyme released by damaged muscle. A test within 72 hours of hard training is uninterpretable
Alanine aminotransferase	<25 U/L	Baseline organ safety for an uncharacterized injected protein	Alanine aminotransferase is a liver enzyme. Conventional upper limits reach 40–55 U/L, which is too permissive to detect early change
Estimated glomerular filtration rate	>90 mL/min/1.73 m²	Clearance route for protein breakdown products	Estimated glomerular filtration rate reflects kidney filtering capacity. Conventional labs flag only values below 60. Creatinine-based estimates read low when lean mass rises, so cystatin C is the better companion measure
Fasting insulin	2–5 µIU/mL	Tracks the metabolic effect claimed for this pathway	Conventional ranges extend to 25 µIU/mL. Requires a 10–12 hour fast; fasting glucose alongside it allows insulin resistance to be calculated
Glycated hemoglobin	4.9–5.3%	Confirms whether added muscle improves glucose handling	Glycated hemoglobin reflects average blood sugar over roughly three months. Conventional normal extends to 5.7%. Falsely low with short red-cell lifespan; no fasting needed
Follicle-stimulating hormone	1.5–8.0 IU/L (men), cycle-dependent (women)	Detects activin blockade, the off-target effect the design claims to avoid	Follicle-stimulating hormone drives gamete production. Conventional male reference reaches 12.4 IU/L. A morning draw is standard; in women, timing to the early follicular phase is required for interpretation
Grip and knee-extensor strength	≥5% gain from own baseline at 12 weeks	The endpoint that related agents repeatedly failed to move	Not a blood test. The same dynamometer and protocol each time; three attempts, best value recorded

Qualitative markers tracked alongside the numbers:

Cramping frequency and timing, particularly at night
Stool consistency and frequency in the first four weeks
Nosebleeds, easy bruising, or new spider-like vessels on the face and trunk
Perceived recovery between training sessions and session-to-session load tolerance
Fit of clothing at the shoulders and thighs relative to the waist
Injection-site redness, swelling or persistent nodules

Emerging Research

No registered trial of FLGR-242 exists: A search of the trial registry for FLGR-242 and FLGR242 returned no record of any kind, so nothing currently under way will produce direct evidence on this compound.
Follistatin gene therapy for age-related muscle decline (NCT07443826): Phase 1/2, 12 participants, primary endpoints treatment-emergent adverse events and dose-limiting toxicities. The closest registered test of follistatin delivery in aging muscle rather than in disease.
Bimagrumab with tirzepatide for weight management (NCT06643728): Phase 2, 252 adults with obesity or overweight, primary endpoint percent change in body weight. Tests whether receptor blockade protects lean mass during rapid weight loss.
Trevogrumab with semaglutide (NCT06299098): Phase 2, 1005 adults with obesity, co-primary endpoints adverse-event incidence and percent change in lean and fat mass. The largest safety dataset this class will generate.
Bimagrumab and tirzepatide on body composition and bone (NCT05933499): Phase 2, 63 adults, primary endpoint kilograms of lean mass by scan. Its bone endpoints address the weakest-characterized safety area of the class.
Apitegromab in facioscapulohumeral muscular dystrophy (NCT07435129): Phase 2, 60 participants, primary endpoint efficacy versus placebo. A selective myostatin-only agent in the same disease where the follistatin-based trap failed functionally.
Evidence that could strengthen the case: Ozawa et al., 2021 showed a monovalent follistatin-like 3 fusion protein with extended serum half-life produced fiber hypertrophy in mice, supporting the half-life engineering FLGR-242 claims.
Evidence that could weaken the case: Statland et al., 2022 and Hanna et al., 2019 both enlarged muscle without functional gain, and further trials reporting the same dissociation would make the mass endpoint hard to defend.
The open question on selectivity: Whether sparing activin preserves the muscle effect is unresolved, since Lee et al., 2010 found follistatin’s action depends partly on activin. Any binding study of FLGR-242 would settle the design premise.
The open question on specific force: No human trial in this class has measured force per unit of muscle, the endpoint that would show whether new tissue is functional. Amthor et al., 2007 found it reduced in myostatin-null mice.

Conclusion

FLGR-242 is a laboratory-made fragment of follistatin, the body’s own release on the muscle-growth brake, redesigned to travel through the bloodstream and to last far longer than the natural protein. Nothing published describes what it does in a person, or even in an animal. Every claim about how narrowly it acts, how long it lasts and what it does to muscle comes from the company selling it and from writers paid on commission to promote it — the single most important fact about this evidence base. The trials behind the related compounds were also designed and paid for by the firms that owned them, and the anti-doping body that lists this class is funded by governments and sport rather than by its own rulings.

What can be said comes from other compounds aimed at the same brake. Those do add muscle tissue, consistently and measurably. What they have repeatedly failed to do is turn that tissue into more strength or better movement; the gap between size and function is the most reproducible finding in the field. Their side effects cluster around cramping, loose stools, a rise in a blood fat linked to artery disease, and, for the broadest-acting versions, nosebleeds and small surface vessels that ended one development program.

Layered on top is the supply problem. Material sold this way is frequently impure, sometimes carries toxic metals, and cannot be matched to any published standard.

Top - Benefits - Risks - Protocol

FLGR-242 for Muscle Growth

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Medium 🟩 🟩

Low 🟩

Increase in Skeletal Muscle Mass

Improved Physical Function ⚠️ Conflicted

Reduction in Fat Mass ⭕️ Not Central to Muscle Growth

Improved Insulin Sensitivity ⭕️ Not Central to Muscle Growth

Speculative 🟨

Whole-Body Rather Than Local Muscle Growth

Narrower Off-Target Blockade

Preservation of Muscle During Weight Loss

Faster Recovery From Resistance Training

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Medium 🟥 🟥

Low 🟥

Muscle Cramps and Spasms

Diarrhea

Rise in Low-Density Lipoprotein Cholesterol

Nosebleeds and Dilated Skin Vessels

Injection-Site Reactions and Hypersensitivity

Exposure to Impure or Misrepresented Product

Speculative 🟨

Immunogenicity and Neutralizing Antibodies

Reduced Force per Unit of Muscle

Disruption of Reproductive Hormone Signaling

Effects on Bone ⚠️ Conflicted

Unopposed Growth Signaling in Non-Muscle Tissue

Cardiac Remodeling

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion